Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

Jeanette H W Leusen's Biography



Jeanette H W Leusen, Associate Professor & Head of Immunotherapy Group, University Medical Center Utrecht

Dr. Jeanette Leusen, received her PhD in 1995 at the University of Amsterdam, The Netherlands. She became associate professor and head of the immunotherapy group of the University Medical Center in Utrecht in 2006, and head of the UMAB facility in 2012. She has co-authored more than 100 publications in peer-reviewed journals on the working mechanisms of therapeutic antibodies, but also on IgA as a novel class of antibody for the treatment of both malignant as infectious disease.

Jeanette H W Leusen Image

Recruiting Neutrophils with IgA and CD47 Modification to Treat Cancer

Monday, 28 October 2019 at 14:45

Add to Calendar ▼2019-10-28 14:45:002019-10-28 15:45:00Europe/LondonRecruiting Neutrophils with IgA and CD47 Modification to Treat CancerImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

IgA is a strong activator of neutrophils to kill cancer cells. CD47 is a 'don't eat me' signal for cancer cells and healthy cells, that binds to SIRPalpha on neutrophils as an inhibitory receptor or an innate checkpoint molecule. CD47 can be manipulated to not bind to SIRPalpha anymore, and this strongly enhances the IgA anti-tumor effect in vitro and in vivo (Nature Medicine, in press).


Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com